MedTrace Logo

Analysis and Evaluation of Smoking Treatment With Cytisine

NCT06439303 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2024-06-03

No results posted yet for this study

Summary

The lack of clinical studies on the use of Cytisine in the treatment of the cessation of smoking, the need to find effective therapeutic alternatives and the opportunity to reduce costs related to the complications of cigarette smoking, represent the main reasons that led to the design of this study.

Conditions

  • Moderate or Severe Tobacco Use Disorder

Interventions

DRUG

Cytisine 1,5 mg

Administration of Cytisine as monotherapy in the treatment of moderate tobacco use disorder or serious

Sponsors & Collaborators

  • Regina Elena Cancer Institute

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-20
Primary Completion
2024-06-20
Completion
2024-06-20

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06439303 on ClinicalTrials.gov